Johnson & Johnson (NYSE:JNJ) Trading Down 2.1% – Time to Sell?

Johnson & Johnson (NYSE:JNJ)’s share price fell 2.1% on Tuesday . The company traded as low as $237.22 and last traded at $238.1790. 7,099,391 shares traded hands during trading, a decline of 21% from the average session volume of 9,038,657 shares. The stock had previously closed at $243.19.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: HSBC raised its price target on JNJ to $280 and assigned a “buy” rating, implying roughly mid-teens upside from current levels — a direct analyst endorsement that could support further upside if investors follow suit. HSBC raises JNJ price target to $280
• Positive Sentiment: Multiple analyst pieces highlight a path to $280, citing strong recent performance (JNJ has outperformed over the past year) and pipeline/portfolio catalysts — these bullish narratives can attract buyers and lift sentiment. Why One Analyst Thinks Johnson & Johnson Reaches $280 Why One Analyst Thinks Johnson & Johnson Reaches $280 (247WallSt)
• Positive Sentiment: Clinical/regulatory progress: J&J reported a positive Phase I result for its bladder cancer therapy (Erda‑iDRS) with strong response and durable control, and is advancing mid/late‑stage studies — clinical wins can materially improve biotech valuation optionality. JNJ’s Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
• Positive Sentiment: Teclistamab (TECVAYLI) push in oncology: J&J filed a Type II variation with the EMA seeking approval for TECVAYLI in relapsed/refractory multiple myeloma — successful labeling in Europe would expand commercial opportunity. JNJ Targets Opportunities around Multiple Myeloma with TECVAYLI
• Positive Sentiment: Medical device expansion: J&J launched a pulsed field ablation (PFA) technology in Peru for atrial fibrillation, demonstrating ongoing commercialization of new device technology that can support durable med‑tech revenue growth. Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
• Neutral Sentiment: Market context/valuation check: Several writeups ask whether JNJ still offers value after strong multi‑year gains; these pieces analyze implied expectations and could temper some investors’ enthusiasm while others view the run as evidence of momentum. Is It Time To Reassess Johnson & Johnson After Strong Multi Year Share Price Gains
• Neutral Sentiment: Technical/market commentary suggests an extended rally where buyers may need patience — helpful for timing but not an immediate fundamental change. Johnson & Johnson (JNJ) Forecast: Extended Rally Signals Patience for Buyers
• Neutral Sentiment: Related industry news (Monte Rosa supply agreement) appears in feeds but does not directly affect JNJ fundamentals; treat as background. Monte Rosa Therapeutics Announces Clinical Supply Agreement
• Negative Sentiment: Near‑term sell pressure/profit‑taking: despite the positive analyst calls and pipeline news, JNJ is trading lower today — likely reflecting short‑term profit‑taking after strong YTD and 1‑year gains, plus below‑average intraday volume, which can amplify downward moves.

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. Argus boosted their target price on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Loop Capital set a $220.00 price target on Johnson & Johnson in a research note on Tuesday, January 27th. Morgan Stanley set a $262.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. Finally, Stifel Nicolaus boosted their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $236.57.

Johnson & Johnson Price Performance

The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a market cap of $573.68 billion, a PE ratio of 21.55, a P/E/G ratio of 2.38 and a beta of 0.34. The firm has a 50 day moving average of $232.69 and a two-hundred day moving average of $207.13.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Insider Activity

In related news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,142 shares of company stock valued at $7,360,528 over the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Brighton Jones LLC raised its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. United Bank increased its position in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. boosted its position in Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. grew its stake in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.